SEARCH

SEARCH BY CITATION

References

  • 1
    American Thoracic Society. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162: 23412351.
  • 2
    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January1995 (updated 2002, 2003; accessed 26 October 2004). At: http://www.ginasthma.com.
  • 3
    Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35: 657665.
  • 4
    Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998;157: 18041809.
  • 5
    European Network for Understanding Mechanisms of Severe Asthma (ENFUMOSA). The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22: 470477.
  • 6
    Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;2: CD000391.
  • 7
    Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;2: CD002985.
  • 8
    Evans DJ, Cullinan P, Geddes DM. Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;2: CD002987.
  • 9
    Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B et al. Treatment of steroid-dependent bronchial asthma with cyclosporine. Eur Respir J 1995;8: 10911099.
  • 10
    Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23: 723729.
  • 11
    Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12: 13221326.
  • 12
    Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9: 636642.
  • 13
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184190.
  • 14
    Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254261. Erratum in: Eur Respir J 2001;18: 739–740.
  • 15
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34: 632638.
  • 16
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59: 701708.
  • 17
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59: 709717.
  • 18
    Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20: 10881094.
  • 19
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91: 154159.
  • 20
    Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20: 7378.
  • 21
    Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17: 233240.
  • 22
    Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111: 8790.
  • 23
    Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma. Chest 2004;125: 13781386.
  • 24
    Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47: 7683.
  • 25
    Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19: 491498.
  • 26
    Committee on Proprietary Medicinal Products. Notes for guidance on adjustment for baseline covariates. CPMP/EWP/2863/99, 2003.
  • 27
    Weber EJ, Silverman RA, Callaham ML, Pollack CV, Woodruff PG, Clark S et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 2002;113: 371378.
  • 28
    Hartert TV, Speroff T, Togias A, Mitchel EF Jr, Snowden MS, Dittus RS et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89: 467473.
  • 29
    Taylor WR, Newacheck PW. Impact of childhood asthma on health. Pediatrics 1992;90: 657662.
  • 30
    Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149 (3 Pt 1): 604610.
  • 31
    Burr ML, Davies BH, Hoare A, Jones A, Williamson IJ, Holgate SK et al. A confidential inquiry into asthma deaths in Wales. Thorax 1999;54: 985989.
  • 32
    Jalaludin BB, Smith MA, Chey T, Orr NJ, Smith WT, Leeder SR. Risk factors for asthma deaths: a population-based, case-control study. Aust N Z J Public Health 1999;23: 595600.